Banys P
University of California, San Francisco.
J Psychoactive Drugs. 1988 Jul-Sep;20(3):243-61. doi: 10.1080/02791072.1988.10472495.
Disulfiram is a potent alcohol-sensitizing drug, the effectiveness of which remains unproven in the treatment of alcoholism after 40 years of use. Its clinical utility is more closely associated with nonspecific, nonpharmacological factors (such as social class, patient compliance, patient personality characteristics, and treatment structure) than with its aversive biochemistry. Disulfiram is not effective as a sole alternative to a structured treatment program. Disulfiram retains a place in standard alcoholism treatment programs because clinicians have found this agent useful for selected alcoholic patients. Clinical studies and clinical lore describe these patients as older, relapse-prone, socially stable, cognitively intact, not depressed, compulsive, capable of following rules, and tolerant of dependence. Another distinctly responsive (but evasive) group is court-probated patients. These characteristics also describe patients who are well-known to have good outcomes without disulfiram, thus they do not help clinicians to select suitable patients for this medication. Consequently, this article proposes the following selection criteria: (1) patients who can tolerate a treatment relationship; (2) patients who are relapse-prone (but in treatment); (3) patients who have failed with less structured approaches; (4) patients in early abstinence who are in crisis or under severe stress; (5) patients in established recovery for whom individual or group psychotherapy is a relapse risk; and (6) patients who specifically request it. With or without disulfiram, a treatment program needs to be highly structured and predictable in order to be useful to newly recovering patients. Recovery is a process with discernible phases of development, and the provision of structure is the core of early treatment, where behavior change is more important than insight. A well-structured program will have phases through which a patient may progress. Generally speaking, disulfiram is most useful early to establish sobriety and to allow time for other support structures, such as AA, therapist-patient relationships, and new personal relationships, to take hold. Disulfiram is best given to patients with prior treatment failures, early in treatment, briefly during crises in established sobriety, or to support unusual stresses, such as psychotherapy. Prescriptions should be short-term and not allow automatic refills. It should be necessary to attend a treatment program in order to obtain them. Supervision and monitoring dramatically increase compliance.(ABSTRACT TRUNCATED AT 400 WORDS)
双硫仑是一种强效的酒精增敏药物,在使用40年后,其在治疗酒精中毒方面的有效性仍未得到证实。与其厌恶的生物化学作用相比,其临床效用与非特异性、非药理学因素(如社会阶层、患者依从性、患者个性特征和治疗结构)的关联更为紧密。双硫仑作为结构化治疗方案的唯一替代方法并不有效。双硫仑在标准酒精中毒治疗方案中仍占有一席之地,因为临床医生发现这种药物对某些酒精中毒患者有用。临床研究和临床经验表明,这些患者年龄较大、容易复发、社会稳定、认知健全、无抑郁情绪、有强迫倾向、能够遵守规则且耐受依赖。另一个明显有反应(但难以捉摸)的群体是缓刑患者。这些特征也描述了那些众所周知在不使用双硫仑的情况下也有良好预后的患者,因此它们无助于临床医生选择适合使用这种药物的患者。因此,本文提出以下选择标准:(1)能够耐受治疗关系的患者;(2)容易复发(但正在接受治疗)的患者;(3)采用结构化程度较低的方法治疗失败的患者;(4)处于早期戒酒阶段且处于危机或严重压力下的患者;(5)已确立康复状态但个体或团体心理治疗会使其有复发风险的患者;(6)特别要求使用双硫仑的患者。无论是否使用双硫仑,治疗方案都需要高度结构化且可预测,以便对刚康复的患者有用。康复是一个有明显发展阶段的过程,提供结构是早期治疗的核心,在这个阶段行为改变比洞察力更重要。一个结构良好的方案会有患者可以经历的阶段。一般来说,双硫仑在早期最有助于确立戒酒状态,并为其他支持结构(如匿名戒酒互助会、治疗师 - 患者关系和新的人际关系)扎根留出时间。双硫仑最好给予之前治疗失败的患者,在治疗早期、在已确立戒酒状态的危机期间短期使用,或用于应对特殊压力,如心理治疗。处方应该是短期的,不允许自动续方。必须参加治疗方案才能获得处方。监督和监测能显著提高依从性。(摘要截取自400字)